FDA approves new treatment for eosinophilic granulomatosis with polyangiitis

Author(s):

fda treatment eosinophilic granulomatosis polyangiitis autoimmune disease vasculitis therapy approve stamp

On Dec. 12, the U.S. Food and Drug Administration (FDA) approved use of Nucala (mepolizumab) to treat adult patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare autoimmune disease that causes vasculitis. This new indication if the first FDA-approved therapy for EGPA.

Read more via Fda.gov.

LEAVE A REPLY

Please enter your comment!
Please enter your name here